Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma

Toxicology and Applied Pharmacology

Volumn 286, Issue 2, 2015, Pages 112-123

  Qin, Tian ^a   Wang, Chenlong ^a   Chen, Xuewei ^a   Duan, Chenfan ^a   Zhang, Xiaoyan ^a   Zhang, Jing ^a   Chai, Hongyan ^b   Tang, Tian ^c   Chen, Honglei ^d   Yue, Jiang ^a   Li, Ying ^a   Yang, Jing ^a  

^a WUHAN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d WUHAN UNIVERSITY   (China)

Author keywords

Dopamine; Glioma; Growth; Macrophage polarization; Vascular normalization; VEGF VEGFR2 signaling

Indexed keywords

ARGINASE 1; BUTACLAMOL; CELL MARKER; CLODRONIC ACID; CXCL9 CHEMOKINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; LEVODOPA; SMALL INTERFERING RNA; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; DACARBAZINE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CAPILLARY DENSITY; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; GLIOMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PERICYTE; PERITONEUM MACROPHAGE; POLARIZATION; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR REGRESSION; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; PATHOLOGY; WISTAR RAT;

RATTUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL MOVEMENT; DACARBAZINE; DOPAMINE; GENE EXPRESSION; GLIOMA; MACROPHAGES; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84930277118     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.03.021     Document Type: Article

References (47)

1. Arjaans M., Oude Munnink T.H., Oosting S.F., Terwisscha van Scheltinga A.G., Gietema J.A., Garbacik E.T., Timmer-Bosscha H., Lub-de Hooge M.N., Schröder C.P., de Vries E.G. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013, 73:3347-3355.
2. Arrillaga-Romany I., Reardon D.A., Wen P.Y. Current status of antiangiogenic therapies for glioblastomas. Expert Opin. Investig. Drugs 2014, 23:199-210.
3. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., Bottazzi B., Doni A., Vincenzo B., Pasqualini F., Vago L., Nebuloni M., Mantovani A., Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
4. Chakroborty D., Sarkar C., Mitra R.B., Banerjee S., Dasgupta P.S., Basu S. Depleted dopamine in gastric cancer tissues dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 2004, 10:4349-4356.
5. Chakroborty D., Sarkar C., Yu H., Wang J., Liu Z., Dasgupta P.S., Basu S. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20730-20735.
6. Chen P., Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int. Rev. Cell Mol. Biol. 2012, 301:1-35.
7. Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., Cyrus N., Brokowski C.E., Eisenbarth S.C., Phillips G.M., Cline G.W., Phillips A.J., Medzhitov R. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513:559-563.
8. Courtnay R., Ngo D.C., Malik N., Ververis K., Tortorella S.M., Karagiannis T.C. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol. Biol. Rep. 2015, 42:841-851.
9. De Palma M., Lewis C.E. Macrophages limit chemotherapy. Nature 2011, 472:303-304.
10. Färber K., Pannasch U., Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci. 2005, 29:128-138.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
12. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
13. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
14. Goel S., Wong A.H., Jain R.K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant Disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006486.
15. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
16. Huang Y., Snuderl M., Jain R.K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011, 19:1-2.
17. Huang Y., Stylianopoulos T., Duda D.G., Fukumura D., Jain R.K. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res. 2013, 73:7144-7146.
18. Isenberg J.S., Hyodo F., Ridnour L.A., Shannon C.S., Wink D.A., Krishna M.C., Roberts D.D. Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia 2008, 10:886-896.
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
20. Kato Y., Okollie B., Raman V., Vesuna F., Zhao M., Baker S.D., Bhujwalla Z.M., Artemov D. Renin-angiotensin system-regulating aminopeptidases in tumor growth of rat C6 gliomas implanted at the subcutaneous region. Anticancer Res. 2012, 32:3675-3682.
21. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
22. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., Wilson H.M. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 2008, 180:6270-6278.
23. Ma J., Pulfer S., Li S., Chu J., Reed K., Gallo J.M. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001, 61:5491-5498.
24. Magnusson P.U., Looman C., Ahgren A., Wu Y., Claesson-Welsh L., Heuchel R.L. Platelet-derived growth factor receptor-β constitutive activity promotes angiogenesis in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2142-2149.
25. McCarty M.F., Somcio R.J., Stoeltzing O., Wey J., Fan F., Liu W., Bucana C., Ellis L.M. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest. 2007, 117:2114-2122.
26. Meredith E.J., Holder M.J., Rosén A., Lee A.D., Dyer M.J., Barnes N.M., Gordon J. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: implications for non-Hodgkin's lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13485-13490.
27. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., Brochet B., Canron M.H., Franconi J.M., Boiziau C., Petry K.G. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 2011, 17:2-15.
28. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
29. Moreno-Smith M., Lu C., Shahzad M.M., Pena G.N., Allen J.K., Stone R.L., Mangala L.S., Han H.D., Kim H.S., Farley D., Berestein G.L., Cole S.W., Lutgendorf S.K., Sood A.K. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin. Cancer Res. 2011, 17:3649-3659.
30. Moreno-Smith M., Lee S.J., Lu C., Nagaraja A.S., He G., Rupaimoole R., Han H.D., Jennings N.B., Roh J.W., Nishimura M., Kang Y., Allen J.K., Armaiz G.N., Matsuo K., Shahzad M.M., Bottsford-Miller J., Langley R.R., Cole S.W., Lutgendorf S.K., Siddik Z.H., Sood A.K. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 2013, 15:502-510.
31. Nguyen T.A., Frank-Cannon T., Martinez T.N., Ruhn K.A., Marvin M., Casey B., Treviño I., Hong J.J., Goldberg M.S., Tansey M.G. Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J. Neuroinflammation 2013, 10:50.
32. Olson J.J., Nayak L., Ormond D.R., Wen P.Y., Kalkanis S.N., AANS/CNS Joint Guidelines Committee The role of cytotoxic chemotherapy in the management of progressive glioblastoma. J. Neurooncol. 2014, 118:501-555.
33. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
34. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Åkerud P., De Mol M., Salomäki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
35. San-Galli F., Vrignaud P., Robert J., Coindre J.M., Cohadon F. Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats. J. Neurooncol. 1989, 7:299-304.
36. Sarkar C., Chakroborty D., Chowdhury U.R., Dasgupta P.S., Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14:2502-2510.
37. Schwarz J.M., Sholar P.W., Bilbo S.D. Sex differences in microglial colonization of the developing rat brain. J. Neurochem. 2012, 120:948-963.
38. Tang J., Li Z., Lu L., Cho C.H. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin. Cancer Biol. 2013, 23:533-542.
39. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
40. Trudler D., Weinreb O., Mandel S.A., Youdim M.B., Frenkel D. DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J. Neurochem. 2014, 129:434-447.
41. Womeldorff M., Gillespie D., Jensen R.L. Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. Neurosurg. Focus. 2014, 6:E8.
42. Yamashita J., Koi K., Yang D.Y., McCauley L.K. Effect of zoledronate on oral wound healing in rats. Clin. Cancer Res. 2011, 17:1405-1414.
43. Yu W., Chai H., Li Y., Zhao H., Xie X., Zheng H., Wang C., Wang X., Yang G., Cai X., Falck J.R., Yang J. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol. Appl. Pharmacol. 2012, 264:73-83.
44. Zaroslinski J.F., Possley L.H., Schwartz R.A., Morris R.N., Carone F.A., Browne R.K. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 1977, 70:2-6.
45. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjällman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95:272-281.
46. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., Kong L.Q., Wang L., Wu W.Z., Tang Z.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16:3420-3430.
47. Zhao H., Zhang X., Chen X., Li Y., Ke Z., Tang T., Chai H., Guo A.M., Chen H., Yang J. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxicol. Appl. Pharmacol. 2014, 279:311-321.